SNN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

1.53B

+8.09%

1.68B

+6.85%

1.49B

+5.97%

Estimates Revision

The market is revising Downward the revenue expectations for Smith & Nephew plc (SNN) for FY2025, with the revenue forecasts being adjusted by -0.05% over the past three months. During the same period, the stock price has changed by -4.39%.

Revenue Estimates for FY2025

Revise Downward

-0.05%

In Past 3 Month

Stock Price

Go Down

-4.39%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 36.05 USD with a low forecast of 34.65 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

34.65

Averages

36.05

High

37.50

Current: 0.000

Low

34.65

Averages

36.05

High

37.50

Morgan Stanley

Overweight

NULL

downgrade

2025-12-15

Reason

Morgan Stanley

Price Target

2025-12-15

downgrade

Overweight

NULL

Reason

Morgan Stanley lowered the firm's price target on Smith & Nephew to 1,482 GBp from 1,563 GBp and keeps an Overweight rating on the shares.

RBC Capital

Outperform

Sector Perform

downgrade

2025-12-15

Reason

RBC Capital

Price Target

2025-12-15

downgrade

Outperform

Sector Perform

Reason

RBC Capital downgraded Smith & Nephew to Sector Perform from Outperform with a price target of 1,350 GBp, down from 1,700 GBp. The firm sees "material risk" of estimate downgrades to the company's 2026 guidance through the year. RBC's recovery thesis is largely played out and the risk of Smith & Nephew's guidance downgrades "now outweighs limited near-term catalysts," the analyst tells investors in a research note.

Canaccord

Hold

downgrade

$36 -> $34

2025-11-11

Reason

Canaccord

Price Target

$36 -> $34

2025-11-11

downgrade

Hold

Reason

Canaccord lowered the firm's price target on Smith & Nephew to $34 from $36 and keeps a Hold rating on the shares. The firm updated its model followong Q3 results and noted the company reiterated its expectations to deliver 5% underlying growth and reiterated its trading profit margin expectations to be between 19.0% and 20.0%, with a stronger margin anticipated in the 2H versus 1H as it works to deliver on operational savings and believes China headwinds should decrease.

Morgan Stanley

NULL -> Overweight

maintain

2025-11-10

Reason

Morgan Stanley

Price Target

2025-11-10

maintain

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Smith & Nephew to 1,563 GBp from 1,547 GBp and keeps an Overweight rating on the shares.

RBC Capital

Jack Reynolds-Clark

maintain

2025-10-20

Reason

RBC Capital

Jack Reynolds-Clark

Price Target

2025-10-20

maintain

Reason

RBC Capital analyst Jack Reynolds-Clark raised the firm's price target on Smith & Nephew to 1,700 GBp from 1,400 GBp and keeps an Outperform rating on the shares.

Bernstein

Outperform

Market Perform

downgrade

$37.50

2025-10-14

Reason

Bernstein

Price Target

$37.50

2025-10-14

downgrade

Outperform

Market Perform

Reason

Bernstein downgraded Smith & Nephew to Market Perform from Outperform with a $37.50 price target. Smith & Nephew's stock has seen a strong rally in 2025 year-to-date based on solid revenue growth and an inflection in Orthopedic profitability, the firm notes. With consensus 2026 EPS now 10% higher than at the start of the year, coupled with a recent recovery in valuation, Bernstein is moving to the sidelines.

Valuation Metrics

The current forward P/E ratio for Smith & Nephew PLC (SNN.N) is 19.54, compared to its 5-year average forward P/E of 17.63. For a more detailed relative valuation and DCF analysis to assess Smith & Nephew PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

17.63

Current PE

19.54

Overvalued PE

20.96

Undervalued PE

14.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.89

Current EV/EBITDA

9.93

Overvalued EV/EBITDA

12.60

Undervalued EV/EBITDA

9.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.37

Current PS

2.21

Overvalued PS

2.87

Undervalued PS

1.87

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 225.8% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SNN News & Events

Events Timeline

No data

News

8.5

2025-11-26Globenewswire

Sintana Secures 75% Shareholder Approval for Challenger Acquisition

2.0

2025-11-06NASDAQ.COM

Smith & Nephew (SNN) Has Reached Oversold Levels

3.5

2025-10-27Newsfilter

Smith+Nephew Comparative Study Reveals PICO◊ sNPWT (-80 mmHg) Outperforms PrevenaTM -125 mmHg sNPWT in Reducing Wound Dehiscence and Healthcare Costs in Cardiovascular and Orthopedic Surgery

People Also Watch

Frequently Asked Questions

What is Smith & Nephew PLC (SNN) stock price today?

The current price of SNN is 33.57 USD — it has decreased -1.73 % in the last trading day.

What is Smith & Nephew PLC (SNN)'s business?

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

What is the price predicton of SNN Stock?

What is Smith & Nephew PLC (SNN)'s revenue for the last quarter?

Smith & Nephew PLC revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Smith & Nephew PLC (SNN)'s earnings per share (EPS) for the last quarter?

Smith & Nephew PLC. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Smith & Nephew PLC (SNN)'s fundamentals?

How many employees does Smith & Nephew PLC (SNN). have?

Smith & Nephew PLC (SNN) has 17349 emplpoyees as of January 10 2026.

What is Smith & Nephew PLC (SNN) market cap?

Today SNN has the market capitalization of 14.25B USD.